|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-3-18
|
|
pubmed:abstractText |
Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G>A [Ala70Thr]), and showed extremely low plasma cytidine deaminase activity and gemcitabine clearance. Our results suggest that homozygous *3 is a major factor causing gemcitabine-mediated severe adverse reactions among the Japanese population.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:CHUJ PJP,
pubmed-author:HasegawaRR,
pubmed-author:IkedaMM,
pubmed-author:KaniwaNN,
pubmed-author:KondoSS,
pubmed-author:MorizaneCC,
pubmed-author:OkusakaTT,
pubmed-author:SaijoNN,
pubmed-author:SaitoYY,
pubmed-author:SawadaJJ,
pubmed-author:SugiyamaEE,
pubmed-author:UenoHH,
pubmed-author:YoshidaTT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
24
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
870-3
|
|
pubmed:dateRevised |
2010-9-23
|
|
pubmed:meshHeading |
pubmed-meshheading:19293806-Aged,
pubmed-meshheading:19293806-Antimetabolites, Antineoplastic,
pubmed-meshheading:19293806-Area Under Curve,
pubmed-meshheading:19293806-Asian Continental Ancestry Group,
pubmed-meshheading:19293806-Cytidine Deaminase,
pubmed-meshheading:19293806-Deoxycytidine,
pubmed-meshheading:19293806-Female,
pubmed-meshheading:19293806-Humans,
pubmed-meshheading:19293806-Male,
pubmed-meshheading:19293806-Middle Aged,
pubmed-meshheading:19293806-Pancreatic Neoplasms,
pubmed-meshheading:19293806-Polymorphism, Single Nucleotide
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
|
|
pubmed:affiliation |
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hiueno@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
